FDA clears Xcision's breast cancer radiotherapy device

Medical technology company Xcision Medical Systems has received 510(k) clearance...Read more on AuntMinnie.com
Source: AuntMinnie.com Headlines - Category: Radiology Source Type: news

Related Links:

Jesse M. Mast, Periannan Kuppusamy
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Erik W. J. Mollen, Jonathan Ient, Vivianne C. G. Tjan-Heijnen, Liesbeth J. Boersma, Lucio Miele, Marjolein L. Smidt, Marc A. G. G. Vooijs
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Source: Anti-Cancer Agents in Medicinal Chemistry - Category: Cancer & Oncology Authors: Tags: Review article Source Type: research
Soizic Garaud, Pawel Zayakin, Laurence Buisseret, Undine Rulle, Karina Silina, Alexandre de Wind, Gert Van den Eyden, Denis Larsimont, Karen Willard-Gallo, Aija Lin ē
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
The same smartphone technology that can recognize a user's face and voice can now identify breast cancer tumors, a recent study said.
Source: Health News - UPI.com - Category: Consumer Health News Source Type: news
Authors: Haagenson KK, Zhang JW, Xu Z, Shekhar MPV, Wu GS Abstract [This corrects the article DOI: 10.18632/oncotarget.1795.]. PMID: 30443298 [PubMed - in process]
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
Authors: Kim S, Tiedt R, Loo A, Horn T, Delach S, Kovats S, Haas K, Engstler BS, Cao A, Pinzon-Ortiz M, Mulford I, Acker MG, Chopra R, Brain C, di Tomaso E, Sellers WR, Caponigro G Abstract Inhibition of cyclin-dependent kinases 4 and 6 (CDK4/6) is associated with robust antitumor activity. Ribociclib (LEE011) is an orally bioavailable CDK4/6 inhibitor that is approved for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer, in combination with an aromatase inhibitor, and is currently being evaluated in several additional trials. Here, we report the p...
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
This article highlights NCCN's position on screening mammography and the screening controversy. PMID: 30442738 [PubMed - in process]
Source: Journal of the National Comprehensive Cancer Network : JNCCN - Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research
Authors: Thomas PS Abstract Atypical hyperplasia (AH) and lobular carcinoma in situ (LCIS) are nonmalignant breast lesions that confer a 4- to 10-fold increased risk for breast cancer in women. Often, AH and LCIS are diagnosed through breast biopsy due to a mammographic or palpable finding. Although AH and LCIS are benign breast disease, further management is necessary due to their high-risk nature and premalignant potential. Over the decades, management of AH and LCIS has changed as more is learned about these disease processes. This review explores the studies evaluating the risk for breast cancer in women with A...
Source: Journal of the National Comprehensive Cancer Network : JNCCN - Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research
Authors: Bevers TB, Helvie M, Bonaccio E, Calhoun KE, Daly MB, Farrar WB, Garber JE, Gray R, Greenberg CC, Greenup R, Hansen NM, Harris RE, Heerdt AS, Helsten T, Hodgkiss L, Hoyt TL, Huff JG, Jacobs L, Lehman CD, Monsees B, Niell BL, Parker CC, Pearlman M, Philpotts L, Shepardson LB, Smith ML, Stein M, Tumyan L, Williams C, Bergman MA, Kumar R Abstract The NCCN Guidelines for Breast Cancer Screening and Diagnosis have been developed to facilitate clinical decision making. This manuscript discusses the diagnostic evaluation of individuals with suspected breast cancer due to either abnormal imaging and/or physical fi...
Source: Journal of the National Comprehensive Cancer Network : JNCCN - Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Radiology